Bizarre Patents
Smoking Cessation Lighter and Method
A lighter for tobacco products suppresses the urge to smoke by operant conditioning.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7662862 | 5-HTreceptor antagonists The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutica... | 02/16/2010 |
| 7619007 | Method and composition for administering an NMDA receptor antagonist to a subject The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. ... | 11/17/2009 |
| 7456224 | Method for treating autism A method for treating autism comprising the step of administering an effective amount of a medicament characterized as a NMDA-receptor antagonist or a pharmaceutically acceptable salt thereof. ... | 11/25/2008 |
| 7456223 | Treatment of bruxism A composition and its use for local percutaneous delivery of a drug, in particular a muscle relaxant, more particularly cyclobenzaprine present in an amount of about 1 to about 10% by weight of the composition in an organogel cream are disclosed. The composition is ... | 11/25/2008 |
| 7422110 | Titration/compliance pack with increasing doses A titration package and method for enabling compliance with a regime of changing dosage of medication over a period of time includes a backing having an array of receivers with the array including a plurality of columns and a plurality of rows. A plurality of sets o... | 09/09/2008 |
| 7086532 | Titration/compliance pack with increasing doses A titration package and method for enabling compliance with a regime of changing dosage of medication over a period of time includes a backing having an array of receivers with the array including a plurality of columns and a plurality of rows. A plurality of sets o... | 08/08/2006 |
| 6974814 | Neuropharmacological treatment of sleep-related breathing disorders The present invention relates to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess glutamate-related and/or glycine-related pharmacological activity or ... | 12/13/2005 |
| 6632843 | Treatment of bruxism This invention relates to the use of a composition for local percutaneous delivery of a drug such as a muscle relaxant, more particularly cyclobenzaprine in an organogel cream. The composition is applied by the patient directly to the skin over accessible... | 10/14/2003 |
| 6620845 | Aminoadamantane derivatives as therapeutic agents The present invention provides novel aminoadamantane derivatives, methods of making the derivatives, compositions including the novel aminoadamantane derivatives, and methods for the treatment and prevention of neurological diseases using the derivatives ... | 09/16/2003 |
| 6576636 | Method of treating a liver disorder with fatty acid-antiviral agent conjugates The invention provides conjugates of fatty acids and antiviral agents useful in treating liver disorders.... | 06/10/2003 |
| 6531511 | 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission The use of a compound of formula (1), as disclosed in the specification, wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl and aryl, or pharmaceutically acce... | 03/11/2003 |
| 6444702 | Aminoadamantane derivatives as therapeutic agents The present invention provides novel aminoadamantane derivatives, methods of making the derivatives, compositions including the novel aminoadamantane derivatives, and methods for the treatment and prevention of neurological diseases using the derivatives ... | 09/03/2002 |
| 6384083 | USE OF ADAMANTANE AMINES OR STRUCTURALLY SIMILAR COMPOUNDS FOR COMBATING BORNA DISEASE VIRUS AND FOR THE PREVENTION AND TREATMENT OF AFFECTIVE DISEASES AND OTHER DISORDERS ASSOCIATED WITH BDV INFECTIONS IN HUMANS AND ANIMALS The invention concerns the use of 1-adamantane amines (amantadines) or structurally similar compounds for combating borna disease virus infections and for treating affective diseases and disorders associated with borna disease virus infections in humans a... | 05/07/2002 |
| 6271264 | Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants The present invention relates to a method for sequestering bile acids in a patient and to particular polymers for use in the method. The method comprises administering a therapeutically effective amount of a spirobicyclic ammonium moiety-containing polyme... | 08/07/2001 |
| 6114392 | Agmatine, and polyaminoguanidine-bound heterocyclic compounds for neurotrauma and neurodegenerative diseases The invention relates to the use of agmatine, in the treatment of acute neurotrauma (such as stroke) and degenerative disorders of the central and peripheral nervous system (such as dementia). The invention further provides novel compounds of general formula I... | 09/05/2000 |
| 6066652 | Method for treating diseases of the inner ear using adamantane derivatives Use of adamantane derivatives of the formula ##STR1## in which R1 and R2 are identical or different and can be hydrogen or straight-chained or branched alkyl groups having 1 to 6 carbon atoms, or together with the nitrogen atom can represent a heterocycli... | 05/23/2000 |
| 5962463 | Methods of stimulating non-amyloidogenic processing of the amyloid precursor protein Stimulating non-amyloidogenic processing by the activation of cell surface serotonin receptors linked to phospholipase and protein kinase C is described. Activation of the cell surface serotonin receptors is accomplished by contacting the cell with an age... | 10/05/1999 |
| 5955501 | Protein kinase C modulators O Compounds having anti-inflammatory and other activities are disclosed. The compounds are derived from phorboids of the diterpene- and benzolactam-classes.... | 09/21/1999 |
| 5939425 | Method for treating a migraine The migraine-treating effectiveness of a local anesthetic drug is significantly enhanced by coadministering dextromethorphan or dextrorphan.... | 08/17/1999 |
| 5891885 | Method for treating migraine The migraine-treating effectiveness of an antimigraine drug is significantly enhanced by administering a selective 5-HT1 agonist together with dextromethorphan or dextrorphan.... | 04/06/1999 |
| 5886051 | Methods and compositions for the treatment of neurodegeneration Methods and pharmaceutical compositions in unit dosage form for treating neurodegeneration in a human or non-human animal afflicted therewith wherein the active agent is a therapeutically effective amount of a polyamine having the formula: ##STR1## ... | 03/23/1999 |
| 5866585 | Methods of treating tardive dyskinesia using NMDA receptor antagonists A method for treating symptoms of patients diagnosed with tardive dyskinesia (TD) using NMDA receptor antagonists is disclosed. This invention illustrates that certain NMDA-receptor antagonists are effective pharmacologic agents in the treatment of hyperk... | 02/02/1999 |
| 5750568 | Protein kinase C Modulators. L. Pharmaceutical compositions having antiviral, antiinflammatory and other activities are disclosed. The compositions are of compounds derived from diterpene phorboids.... | 05/12/1998 |
| 5643948 | Protein kinase C modulators. K. Compounds having anti-inflammatory and other activities are disclosed. The compounds are derived from diterpenes of the phorbol-, resiniferonol- and ingenol-classes.... | 07/01/1997 |
| 5614509 | Pharmaceutical agents for preventing the development of tolerance during the treatment with benzodiazepine-receptor-binding active ingredients The use of NMDA receptor antagonists or their physiologically compatible salts for preventing the development of tolerance during the long-term treatment with benzodiazepine-receptor-binding active ingredients as well as the combination of new pharmaceuti... | 03/25/1997 |
| 5614560 | Method of preventing NMDA receptor-mediated neuronal damage Disclosed is a method for reducing non-ischemic NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a compound of the formula shown in FIG. 1 (or a physiologically-acceptable salt thereof), wherein R1 includes an a... | 03/25/1997 |
| 5597809 | Treatment of optic neuritis Methods of treating optic neuritis comprising administering a protective agent which inhibits glutamate-mediated retinal cell damage to a mammal at risk of developing optic neuritis.... | 01/28/1997 |
| 5596020 | Amino bi- and tri-carbocyclic alkane bis-aryl squalene synthase inhibitors This invention relates to a class of novel amino bi- and tri-carbocyclic alkane compounds having bis-aryl substitution which exhibit squalene synthase inhibition properties. The bi- and tri-carbocyclic alkane ring contains an amino group and the ring is f... | 01/21/1997 |
| 5576355 | Diamondoid derivatives for pharmaceutical use A method of inhibiting viruses in which a virus is contacted with diamondoid alcohol, ketone, ketone derivative, adamantyl amino acid, quaternary salt or combinations thereof which have antiviral properties. These diamondoid derivatives are shown to have ... | 11/19/1996 |
| 5506231 | Treatment of aids dementia, myelopathy and blindness Damage to CNS neurons of a human patient infected with a human immunodeficiency virus is reduced by administering an antagonist of the NMDA receptor complex.... | 04/09/1996 |
| 5334618 | Method of preventing NMDA receptor-mediated neuronal damage Disclosed is a method for reducing non-ischemic NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a compound of the formula shown in FIG. 1 (or a physiologically-acceptable salt thereof), wherein R1 includes an a... | 08/02/1994 |
| 5326786 | 5,6,7,9-tetrahydro-1,2,3-trimethoxy-9-oxobenzo[alpha]heptalene derivative and pharmaceutical use Compounds represented by the formula ##STR1## wherein R1 and R2 each represent a hydrogen atom or a protective group for a hydroxyl group, or R1 and R2 combine to represent a protective group for hydroxyl g... | 07/05/1994 |
| 5158775 | Aerosols of pyrido [1,2-a]pyrimidine compounds A suspension type aerosol inhalations containing (a) 0.015 to 5.00% (w/w) of a pyrido[1,2-a]pyrimidine compound of the formula: ##STR1## where R is a n-propyl or allyl group, A is a tetrazolyl or carboxyl group, and n is a whole number of 0 to 2, and... | 10/27/1992 |
| 5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R1 and R2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1... | 10/29/1991 |
| 4351847 | Antiviral alpha, alpha-dialkyl adamantylethylamines Warm-blooded animals are treated by administering to the animal a dosage, effective to prevent or to alleviate the symptoms of herpes virus, type II, of a compound of the formula I or its acid salt: ##STR1## wherein R1 and R2 ar... | 09/28/1982 |
| 4346112 | Composition and method for treating patients having Parkinson's Disease Parkinson's Disease in animals is treated by administering to the animal 3-ethyl-aminodamantane in a pharmaceutically acceptable carrier.... | 08/24/1982 |
| 4283422 | 3-Amino-4-homoisotwistane derivatives Novel 3-amino-4-homoisotwistane derivatives of the formula, ##STR1## wherein R1 is a hydrogen atom, a C1 -C4 alkyl group or a C3 -C5 alkenyl group, and R2 is a C1 -C4 ... | 08/11/1981 |
| 4248891 | 1-(1-Aminoalkyl)tricyclo[4,3,1,12,5 ]undecanes Compounds having the formula ##STR1## in which R is lower alkyl, and acid addition salts of said compounds. The compounds possess anti-RNA-viral activity and also an antiviral activity against herpes virus.... | 02/03/1981 |
| 4230725 | Antiviral agent Antiviral agents containing an effective amount of 1-amino-2,4-ethanobicyclo[3,3,1]nonane or salts thereof which are effective for the treatment or prevention of infectious diseases caused by herpes or influenza virus.... | 10/28/1980 |
| 4210647 | Antiviral combinations Antiviral combinations containing a 2-ester-substituted-3,4-dihydro-3-oxoquinoxaline and a hindered amine.... | 07/01/1980 |
